Patents by Inventor Zhiguo Jake Song
Zhiguo Jake Song has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230287032Abstract: The present invention relates to efficient processes useful in the preparation of fluorinated nucleosides, such as (O—{[(2R,3R,4S,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-3-hydroxyoxolan-2-yl]methyl}O,O-dihydrogen phosphorothioate, also known as 2?-(S)-fluoro-thio-adenosine monophosphate or 2?-F-thio-AMP. Such fluorinated nucleosides may be useful as a biologically active compound and or as an intermediate for the synthesis of more complex biologically active compounds. The present invention also encompasses intermediates useful in the disclosed synthetic processes and the methods of their preparation.Type: ApplicationFiled: August 11, 2021Publication date: September 14, 2023Applicant: Merck Sharp & Dohme LLCInventors: Cheol Keun Chung, Zhijian Liu, Peter E. Maligres, Edna Mao, Jennifer V. Obligacion, Eric M. Phillips, Michael Pirnot, Marc Poirier, Zhiguo Jake Song, Tao Wang
-
Publication number: 20230174567Abstract: The present invention relates to efficient processes useful in the preparation of fluorinated nucleosides, such as (2S,3R,4S,5R)-5-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-3-fluoro-4-hydroxy-2-(mercaptomethyl)tetrahydrofuran-3-yl dihydrogen phosphate, also known as 3?-fluoro-thio-guanosine monophosphate or 3?-F-thio-GMP. Such fluorinated nucleosides may be useful as a biologically active compound and or as an intermediate for the synthesis of more complex biologically active compounds. The present invention also encompasses intermediates useful in the disclosed synthetic processes and the methods of their preparation.Type: ApplicationFiled: May 20, 2021Publication date: June 8, 2023Applicant: Merck Sharp & Dohme LLCInventors: Travis Armiger, Kevin M. Belyk, Tamas Benkovics, Cheol K. Chung, Yining Ji Chen, Heather Claire Johnson, Artis Klapars, Zhijian Liu, Zhuqing Liu, Jeffrey C. Moore, Andrew J. Neel, Feng Peng, Stephan M. Rummelt, Nastaran Salehi Marzuarani, Benjamin D. Sherry, Zhiguo Jake Song, Ben William Hulme Turnbull, Lu Wang, Feng Xu
-
Publication number: 20210154221Abstract: The present invention is directed to 4?-substituted nucleoside derivatives of Formula I and their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS and/or ARC. The present invention also provides processes for the preparation of 4?-substituted nucleoside derivatives of Formula I and derivatives thereof.Type: ApplicationFiled: February 3, 2021Publication date: May 27, 2021Applicants: Merck Sharp & Dohme Corp., Merck Sharp & Dohme LimitedInventors: Mark McLaughlin, Edward Cleator, Jongrock Kong, Andrew William Gibson, David R. Lieberman, Alejandro Diequez Vazquez, Stephen Philip Keen, Michael J. Williams, Jeffrey C. Moore, Erika M. Milczek, Feng Peng, Kevin M. Belyk, Zhiguo Jake Song
-
Publication number: 20190022115Abstract: The present invention is directed to 4?-substituted nucleoside derivatives of Formula (I) and their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS and/or ARC. The present invention also provides processes for the preparation of 4?-substituted nucleoside derivatives of Formula (I) and derivatives thereof.Type: ApplicationFiled: September 16, 2016Publication date: January 24, 2019Applicants: Merck Sharp & Dohme Corp., Merck Sharp & Dohme LimitedInventors: Vinay M. Girijavallabhan, Mark McLaughlin, Edward Cleator, Jongrock Kong, Andrew William Gibson, David R. Lieberman, Alejandro Dieguez Vazquez, Stephen Philip Keen, Michael J. Williams, Jeffrey C. Moore, Erika M. Milczek, Feng Peng, Kevin M. Belyk, Zhiguo Jake Song
-
Patent number: 10053466Abstract: A process for preparing a compound of structural Formula Ia: comprising Boc deprotection with TFA of: ?and reductive amination of:Type: GrantFiled: December 5, 2017Date of Patent: August 21, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: John Y. L. Chung, Feng Peng, Yonggang Chen, Amude Mahmoud Kassim, Cheng-yi Chen, Mathew Maust, Mark McLaughlin, Michael J. Zacuto, Qinghao Chen, Lushi Tan, Zhiguo Jake Song, Yang Cao, Feng Xu
-
Publication number: 20180093992Abstract: A process for preparing a compound of structural Formula Ia: comprising Boc deprotection with TFA of: ?and reductive amination of:Type: ApplicationFiled: December 5, 2017Publication date: April 5, 2018Inventors: John Y. L. Chung, Feng Peng, Yonggang Chen, Amude Mahmoud Kassim, Cheng-yi Chen, Mathew Maust, Mark McLaughlin, Michael J. Zacuto, Qinghao Chen, Lushi Tan, Zhiguo Jake Song, Yang Cao, Feng Xu
-
Patent number: 9873707Abstract: The present invention includes compounds useful as intermediates in the preparation of macrolactams, methods for preparing the intermediates, and methods for preparing macrolactams. One use of the methods and intermediates described herein is in the production of macrolactam compounds able to inhibit HCV NS3 protease activity. HCV NS3 inhibitory compounds have therapeutic and research applications.Type: GrantFiled: October 14, 2014Date of Patent: January 23, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Feng Xu, Richard Desmond, Guy R. Humphrey, Hongming Li, Ji Qi, Rebecca T. Ruck, Zhiguo Jake Song, Tao Wang, Yong-Li Zhong, Jeonghan Park, Laura Marie Artino, Richard John Varsolona
-
Patent number: 9862725Abstract: A process for preparing a compound of structural Formula Ia: comprising Boc deprotection with TFA of, reductive amination of:Type: GrantFiled: July 16, 2015Date of Patent: January 9, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: John Y. L. Chung, Feng Peng, Yonggang Chen, Amude Mahmoud Kassim, Cheng-yi Chen, Mathew Maust, Mark McLaughlin, Michael J. Zacuto, Qinghao Chen, Lushi Tan, Zhiguo Jake Song, Yang Cao, Feng Xu
-
Publication number: 20170233382Abstract: This invention provides processes for the preparation of verubecestat (Compound of Formula (I)), a potent inhibitor of BACE-1 and BACE-2. In addition, the invention provides certain synthetic intermediates which are useful, among other things, for the preparation of the Compound of Formula (I).Type: ApplicationFiled: August 10, 2015Publication date: August 17, 2017Applicant: Merck Sharp & Dohme Corp.Inventors: Steven P. Miller, Carmela Molinaro, David Thaisrivongs, Feng Xu, Richard Desmond, Hongming Li, Qinghao Chen, Andrew W. Stamford, Zhiguo Jake Song, Lushi Tan
-
Publication number: 20170158701Abstract: A process for preparing a compound of structural Formula Ia: comprising Boc deprotection with TFA of, reductive amination of:Type: ApplicationFiled: July 16, 2015Publication date: June 8, 2017Inventors: John Y. L. Chung, Feng Peng, Yonggang Chen, Amude Mahmoud Kassim, Cheng-yi Chen, Mathew Maust, Mark McLaughlin, Michael J. Zacuto, Qinghao Chen, Lushi Tan, Zhiguo Jake Song, Yang Cao, Feng Xu
-
Publication number: 20160251375Abstract: The present invention includes compounds useful as intermediates in the preparation of macrolactams, methods for preparing the intermediates, and methods for preparing macrolactams. One use of the methods and intermediates described herein is in the production of macrolactam compounds able to inhibit HCV NS3 protease activity. HCV NS3 inhibitory compounds have therapeutic and research applications.Type: ApplicationFiled: October 14, 2014Publication date: September 1, 2016Applicant: Merck Sharp & Dohme Corp.Inventors: Feng XU, Richard DESMOND, Guy R. HUMPHREY, Hongming LI, Ji QI, Rebecca T. RUCK, Zhiguo Jake SONG, Tao WANG, Yong-Li ZHONG, Jeonghan PARK, Laura Marie ARTINO, Richard John VARSOLONA
-
Patent number: 9238604Abstract: The present invention includes compounds useful as intermediates in the preparation of macrolactams, methods for preparing the intermediates, and methods for preparing macrolactams from the intermediates. One use of the methods and intermediates described herein is in the production of macrolactam compounds able to inhibit HCV NS3 protease activity. HCV NS3 inhibitory compounds have therapeutic and research applications.Type: GrantFiled: August 16, 2012Date of Patent: January 19, 2016Assignee: Merck Sharp & Dohme Corp.Inventors: Feng Xu, Guy Humphrey, Tao Pei, Zhiguo Jake Song, Tao Wang, Laura Artino
-
Patent number: 8987463Abstract: Described herein are novel methods of preparing a compound of Formula II or a pharmaceutically acceptable salt thereof. In some embodiments, the method is for preparing betrixaban or a pharmaceutically acceptable salt thereof. Also described are compositions comprising substantially pure betrixaban free base or salt thereof.Type: GrantFiled: February 1, 2013Date of Patent: March 24, 2015Assignees: Millennium Pharmaceuticals, Inc., Portola Pharmaceuticals, Inc.Inventors: Anjali Pandey, Emilia P. T. Leitao, Jose Rato, Zhiguo Jake Song
-
Publication number: 20140200343Abstract: The present invention includes compounds useful as intermediates in the preparation of macrolactams, methods for preparing the intermediates, and methods for preparing macrolactams from the intermediates. One use of the methods and intermediates described herein is in the production of macrolactam compounds able to inhibit HCV NS3 protease activity. HCV NS3 inhibitory compounds have therapeutic and research applications.Type: ApplicationFiled: August 16, 2012Publication date: July 17, 2014Inventors: Feng Xu, Guy Humphrey, Tao Pei, Zhiguo Jake Song, Tao Wang, Laura Artino
-
Patent number: 8637449Abstract: The present invention relates to synthetic processes useful in the preparation of macrocyclic compounds of Formula (I) that are useful as inhibitors of the hepatitis C virus NS3 protease and have application in the treatment of conditions caused by the hepatitis C virus. The present invention also encompasses intermediates useful in the disclosed synthetic processes and the methods of their preparation.Type: GrantFiled: August 26, 2010Date of Patent: January 28, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Zhiguo Jake Song, Yaling Wang, David M. Tellers, Laura M. Artino, David R. Lieberman
-
Publication number: 20130338141Abstract: Compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: wherein X1, X2, Y, R1A, R1B, R2 and R3 are defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset or progression of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se (or as hydrates or solvates thereof) or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Processes for making compounds of Formula I and intermediates thereof are also described.Type: ApplicationFiled: August 19, 2013Publication date: December 19, 2013Inventors: Richard C. Isaacs, Wayne J. Thompson, Peter D. Williams, Dai-Shi Su, Shankar Venkatraman, Mark W. Embrey, Thorsten E. Fisher, John S. Wai, David C. Dubost, Richard G. Ball, Eric J. Choi, Tao Pei, Sarah L. Trice, Neil Campbell, Matthew Maddes, Peter E. Maligres, Michael Shevlin, Zhiguo Jake Song, Dietrich P. Steinhuebel, Neil A. Strotman, Jingjun Yin
-
Patent number: 8513234Abstract: Compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: wherein X1, X2, Y, R1A, R1B, R2 and R3 are defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset or progression of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se (or as hydrates or solvates thereof) or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Processes for making compounds of Formula I and intermediates thereof are also described.Type: GrantFiled: October 2, 2009Date of Patent: August 20, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Richard C. A. Isaacs, Wayne J. Thompson, Peter D. Williams, Dai-Shi Su, Shankar Venkatraman, Mark W. Embrey, Thorsten E. Fisher, John S. Wai, David C. Dubost, Richard G. Ball, Eric J. Choi, Tao Pei, Sarah L. Trice, Neil Campbell, Matthew Maddess, Peter E. Maligres, Michael Shevlin, Zhiguo Jake Song, Dietrich P. Steinhuebel, Neil A. Strotman, Jingjun Yin
-
Patent number: 8394964Abstract: Described herein are novel methods of preparing a compound of Formula II or a pharmaceutically acceptable salt thereof. In some embodiments, the method is for preparing betrixaban or a pharmaceutically acceptable salt thereof. Also described are compositions comprising substantially pure betrixaban free base or salt thereof.Type: GrantFiled: December 15, 2010Date of Patent: March 12, 2013Assignees: Millennium Pharmaceuticals, Inc., Portola Pharmaceuticals, Inc.Inventors: Anjali Pandey, Emilia P. T. Leitao, Jose Rato, Zhiguo Jake Song
-
Publication number: 20120232247Abstract: The present invention relates to synthetic processes useful in the preparation of macrocyclic compounds of Formula (I) that are useful as inhibitors of the hepatitis C virus NS3 protease and have application in the treatment of conditions caused by the hepatitis C virus. The present invention also encompasses intermediates useful in the disclosed synthetic processes and the methods of their preparation.Type: ApplicationFiled: August 26, 2010Publication date: September 13, 2012Inventors: Zhiguo Jake Song, Yaling Wang, David M. Tellers, Laura M. Artino, David R. Lieberman
-
Publication number: 20110319627Abstract: Described herein are novel methods of preparing a compound of Formula II or a pharmaceutically acceptable salt thereof. In some embodiments, the method is for preparing betrixaban or a pharmaceutically acceptable salt thereof. Also described are compositions comprising substantially pure betrixaban free base or salt thereof.Type: ApplicationFiled: December 15, 2010Publication date: December 29, 2011Inventors: Anjali Pandey, Emilia P. T. Leitao, Jose Rato, Zhiguo Jake Song